Correction to: Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury
Correction to: Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury. // Neuropsychopharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0893133X26052541?dgcid=rss_sd_all
Correction to: Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury. Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0893133X26052541?dgcid=rss_sd_all
“Correction to: Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury.” Neuropsychopharmacology.
@article{article94801,
title = {Correction to: Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury},
journal = {Neuropsychopharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0893133X26052541?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...